Related Experiment Video
Updated: Apr 14, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Content and construct validity of the Rheumatic Diseases Comorbidity Index in patients with gout
Bart Spaetgens1, José M A Wijnands2, Caroline van Durme3
1Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, CAPHRI Research Institute, Maastricht University, Maastricht, The Netherlands and bartholomeus.spaetgens@mumc.nl.
Insights
The Rheumatic Diseases Comorbidity Index (RDCI) and a modified version (mRDCI) show good validity for assessing comorbidities in gout patients. These tools help understand how comorbidities impact patient outcomes.
Area of Science:
- Rheumatology
- Clinical Epidemiology
Background:
- Gout is frequently associated with multiple comorbidities.
- Validated comorbidity measures are lacking for clinical studies in gout patients.
Purpose of the Study:
- To evaluate the content and construct validity of the Rheumatic Diseases Comorbidity Index (RDCI) and a modified RDCI (mRDCI) in gout patients.
- To assess the utility of these indices in understanding the impact of comorbidities on patient outcomes.
Main Methods:
- A cross-sectional study of 122 gout patients.
- Data collected via interviews, chart review, and clinical examination.
- RDCI/mRDCI computed and compared with other indices (CCI, FCI) and health outcomes using correlation and regression analyses.
Main Results:
- High correlation (0.86) between RDCI and mRDCI.
- RDCI/mRDCI showed strong correlations with other comorbidity indices (0.72-0.88).
- Both indices demonstrated association with physical functioning, health status, and healthcare costs.
Conclusions:
- The RDCI and mRDCI possess adequate content and construct validity for use in gout research.
- These indices are suitable for evaluating the influence of comorbidities on outcomes in gout patients.
Objective:
Gout has been associated with a large number of co-morbidities. As yet, no co-morbidity measure has been validated for use in clinical studies in gout. This study aims to evaluate the content and construct validity of the Rheumatic Diseases Comorbidity Index (RDCI) and a gout-specifically modified RDCI (mRDCI) in patients with gout.
Methods:
In a cross-sectional sample of 122 patients with gout, data on co-morbidities were obtained during an interview, chart review and clinical examination. The data were used to compute the RDCI/mRDCI, a simple co-morbidity count, the Charlson Comorbidity Index (CCI) and the Functional Comorbidity Index (FCI). Content and construct validity was explored by assessing Spearman correlations between the two RDCI versions and between RDCI/mRDCI and the other co-morbidity indices, as well as demographic and clinical outcomes. In addition, we assessed the independent association between the RDCI/mRDCI and physical functioning (HAQ disability index), physical health (36-Item Short Form Health Survey) and direct health care and non-health care costs using multivariable regression analyses.
Results:
The correlation between the RDCI and mRDCI was 0.86. Correlations between the RDCI/mRDCI and simple co-morbidity count, CCI or FCI varied between 0.72 and 0.88. Correlations with generic and gout-specific health outcomes were moderate and weak, respectively, with slightly better results for the mRDCI. Multivariable analyses showed that both the RDCI and mRDCI contributed to the variation in physical functioning, physical health and direct health care and non-health care costs.
Conclusion:
Both the RDCI and mRDCI have appropriate content and construct validity to evaluate the influence of co-morbidity on outcome in patients with gout.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease I: Introduction
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Rheumatic Heart Disease IV: Nursing Management
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

